Chang David D
President and CEO
Chang David D has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 18, 2026.
On the most recent filing, Chang David D is listed as President and CEO at Allogene Therapeutics, Inc. Inside the rolling window, Chang David D reported no open-market purchases and 2 open-market sales totaling $289K in ALLO. The largest disclosed transaction in the window is a sale of 95,269 ALLO shares on Feb 2, 2026, worth $171K.
Companies traded
Other insiders at ALLO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$289K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Chang David D made?
Chang David D has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Chang David D trade?
Chang David D has filed SEC Form 4 disclosures for 1 company, including ALLO.
When was Chang David D's most recent SEC Form 4 filing?
Chang David D's most recent SEC Form 4 filing on Tracefour is dated Mar 18, 2026.
What is Chang David D's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Chang David D is listed as President and CEO.
What is Chang David D's total buy and sell value in the current window?
Inside the rolling retention window, Chang David D bought $0 and sold $289K based on SEC Form 4 filings.
What was Chang David D's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 95,269 ALLO shares on 2026-02-02, worth $171K, per SEC Form 4 filings.